SCHEDULE: Intracoastal Capital Discloses 4.99% Stake in Bluejay Diagnostics

Intracoastal Capital LLC and its principals have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership in Bluejay Diagnostics, Inc.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership of Bluejay Diagnostics, Inc. Common Stock.
• As of December 31, 2025, the Reporting Persons beneficially owned an aggregate of 91,537 shares of Common Stock, representing approximately 4.99% of the class.
• This ownership consists of 71,243 shares of Common Stock held directly by Intracoastal Capital LLC and 20,294 shares of Common Stock issuable upon exercise of a warrant (Intracoastal Warrant 1) held by Intracoastal.
• The calculation of beneficial ownership is based on 1,814,133 shares of Common Stock outstanding as of November 25, 2025, as reported by Bluejay Diagnostics, Inc., plus the exercisable warrant shares.
• The filing notes that additional shares issuable from Intracoastal Warrant 1 (729,706 shares), Intracoastal Warrant 2 (63 shares), and Intracoastal Warrant 3 (6 shares) are excluded from the reported beneficial ownership due to blocker provisions that prevent ownership from exceeding 4.99% of the Common Stock.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 821,312 shares of Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive. While a 13G is a compliance filing, the disclosure of a significant, passive institutional stake suggests a degree of confidence in the company by the reporting persons.

Positives

• The disclosure of a significant, albeit passive, stake by an institutional investor (Intracoastal Capital LLC) and its principals (Mitchell P. Kopin, Daniel B. Asher) could be interpreted as a vote of confidence in Bluejay Diagnostics, Inc.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive institutional investors who acquire a significant stake (typically between 5% and 20%) in a public company. This filing indicates that Intracoastal Capital LLC and its principals maintain a substantial, albeit passive, interest in Bluejay Diagnostics, Inc., positioning their ownership just below the 5% threshold to avoid the more stringent reporting requirements of a Schedule 13D, which implies an intent to influence or control the issuer.

Stakeholder Impact

• Shareholders: The filing informs existing and potential shareholders about a significant institutional holder and its passive investment intent, which can influence market perception and trading activity.

Key Dates

Keywords

Bluejay Diagnostics, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investor